Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …

Background Randomized phase III trials have established the efficacy of epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors as first-line treatment for EGFR mutation …

Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …

Objective To compare the efficacy and safety of first line treatments for patients with
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …

Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …

Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most
frequent “actionable” alterations in non–small cell lung cancer (NSCLC). Typified by high …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …

Importance Current guidelines recommend both epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) and cytotoxic chemotherapy drugs as standard treatment …